christianinformation.org
Christian Information Ministries
http://www.christianinformation.org/CIMstaff.html
C I M Staff. The staff of CIM is uniquely qualified to address the issues that confront the Christian Church. Is considered to be one of the foremost Christian scholars in the field of Ark Studies. He has also been involved in world view issues for the past thirty-five years of ministry. His understanding of Postmodernism and its influence on the Christian is widely acclaimed. The most comprehensive topical source book focusing on His words and sayings available today! Site Designed and Developed by.
christianinformation.org
Christian Information Ministries
http://www.christianinformation.org/default.asp
Welcome to Christian Information Ministries. Current Events and Featured Articles:. Should a Christian Seek Psychic Awareness? Unequally Yoked: A Spiritual Crisis. The most comprehensive topical source book focusing on His words and sayings available today! Subscribe now for a free CIM e-newsletter which informs Christians about the postmodern world. Sign Up Today! Site Designed and Developed by.
reatapharma.com
Our Story | Home
http://reatapharma.com/about-us/our-story
PH – ILD – CTD. PH – ILD – IPF. PH – ILD – Sarc. PH – ILD – NSIP. Investors & News. News & Events. Events & Presentations. Proxy & Annual Report. Documents & Charters. Creating New Opportunities for Patients. PH – ILD – CTD. PH – ILD – IPF. PH – ILD – Sarc. PH – ILD – NSIP. Investors & News. News & Events. Events & Presentations. Proxy & Annual Report. Documents & Charters. Bardoxolone methyl (formerly designated as RTA 402) is currently in a Phase 2 ( LARIAT. Omaveloxolone is in a Phase 1b/2 study in me...
reatapharma.com
In-Licensing | Home
http://reatapharma.com/our-science/in-licensing
PH – ILD – CTD. PH – ILD – IPF. PH – ILD – Sarc. PH – ILD – NSIP. Investors & News. News & Events. Events & Presentations. Proxy & Annual Report. Documents & Charters. Creating New Opportunities for Patients. PH – ILD – CTD. PH – ILD – IPF. PH – ILD – Sarc. PH – ILD – NSIP. Investors & News. News & Events. Events & Presentations. Proxy & Annual Report. Documents & Charters. New or unknown targets. Unique approaches to modulating validated targets. First-in-class or best-in-class potential. Efficacy in an...
reatapharma.com
Omaveloxolone|Friedreich’s Ataxia | Home
http://reatapharma.com/product-pipeline/rare-diseases/friedreichs-ataxia
PH – ILD – CTD. PH – ILD – IPF. PH – ILD – Sarc. PH – ILD – NSIP. Investors & News. News & Events. Events & Presentations. Proxy & Annual Report. Documents & Charters. Creating New Opportunities for Patients. PH – ILD – CTD. PH – ILD – IPF. PH – ILD – Sarc. PH – ILD – NSIP. Investors & News. News & Events. Events & Presentations. Proxy & Annual Report. Documents & Charters. Omaveloxolone Friedreich’s Ataxia. PH - ILD - CTD. PH - ILD - IPF. PH - ILD - Sarc. PH - ILD - NSIP. Since patients suffering from F...
reatapharma.com
Reata Enrolls First Patient in the MOTOR Study, a Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathies | Home
http://reatapharma.com/reata-enrolls-first-patient-in-the-motor-study-a-phase-2-study-of-the-safety-efficacy-and-pharmacodynamics-of-rta-408-in-the-treatment-of-mitochondrial-myopathies
PH – ILD – CTD. PH – ILD – IPF. PH – ILD – Sarc. PH – ILD – NSIP. Investors & News. News & Events. Events & Presentations. Proxy & Annual Report. Documents & Charters. Creating New Opportunities for Patients. PH – ILD – CTD. PH – ILD – IPF. PH – ILD – Sarc. PH – ILD – NSIP. Investors & News. News & Events. Events & Presentations. Proxy & Annual Report. Documents & Charters. Reata Enrolls First Patient in the…. IRVING, Texas, July 8, 2015. The primary efficacy endpoint is the change in peak workload (Watt...
reatapharma.com
Bard|Pulmonary Arterial Hypertension | Home
http://reatapharma.com/product-pipeline/cardiovascular/pulmonary-arterial-hypertension
PH – ILD – CTD. PH – ILD – IPF. PH – ILD – Sarc. PH – ILD – NSIP. Investors & News. News & Events. Events & Presentations. Proxy & Annual Report. Documents & Charters. Creating New Opportunities for Patients. PH – ILD – CTD. PH – ILD – IPF. PH – ILD – Sarc. PH – ILD – NSIP. Investors & News. News & Events. Events & Presentations. Proxy & Annual Report. Documents & Charters. Bard Pulmonary Arterial Hypertension. Bard Pulmonary Arterial Hypertension. PH - ILD - CTD. PH - ILD - IPF. PH - ILD - Sarc. PH can ...
reatapharma.com
Rare Diseases | Home
http://reatapharma.com/product-pipeline/rare-diseases
PH – ILD – CTD. PH – ILD – IPF. PH – ILD – Sarc. PH – ILD – NSIP. Investors & News. News & Events. Events & Presentations. Proxy & Annual Report. Documents & Charters. Creating New Opportunities for Patients. PH – ILD – CTD. PH – ILD – IPF. PH – ILD – Sarc. PH – ILD – NSIP. Investors & News. News & Events. Events & Presentations. Proxy & Annual Report. Documents & Charters. PH - ILD - CTD. PH - ILD - IPF. PH - ILD - Sarc. PH - ILD - NSIP. In preclinical studies, activation of Nrf2 increases production of...
SOCIAL ENGAGEMENT